Journal of Probiotics & Health
Open Access

Aminoglycosides: A Class of Antibiotics with Potent Bactericidal Activity

Kevin Jamieson^{* *}Correspondence: Kevin Jamieson, Department of Medicine, University of the Andes, Bogota DC, Colombia, Email:

Author info »

Description

Aminoglycosides are a class of antibiotics that are widely used in clinical medicine. They are particularly effective against Gramnegative bacteria, but also have activity against some Grampositive organisms. Aminoglycosides are known for their potent bactericidal activity and rapid onset of action, making them useful in the treatment of severe infections.

The mechanism of action of aminoglycosides is primarily through binding to the 30S subunit of bacterial ribosomes, which leads to inhibition of protein synthesis. This results in the disruption of bacterial metabolism and ultimately, bacterial cell death. Aminoglycosides are also known to cause misreading of the genetic code during translation, leading to the production of abnormal proteins.

Aminoglycosides are administered parenterally, typically by intravenous or intramuscular injection. Due to their hydrophilic nature, they are poorly absorbed orally and are not effective in treating systemic infections when given by this route. Once administered, aminoglycosides are rapidly distributed throughout the body, with high concentrations achieved in the kidney, liver, and other organs.

Aminoglycosides work by binding to the 30S subunit of bacterial ribosomes, disrupting the process of protein synthesis. This leads to the production of abnormal proteins and a disruption of bacterial metabolism, ultimately resulting in bacterial cell death. Aminoglycosides are known for their potent bactericidal activity and rapid onset of action. However, their use is associated with several toxicities, particularly nephrotoxicity and ototoxicity. Dosing must be carefully monitored to prevent toxicity, and their use in clinical practice is governed by a number of factors, including the severity of the infection and the susceptibility of the causative organism [1].

The pharmacokinetics of aminoglycosides are characterized by a rapid distribution phase, a relatively short elimination half-life, and a prolonged post-antibiotic effect. The post-antibiotic effect refers to the continued suppression of bacterial growth even after the drug has been eliminated from the body. This effect is particularly important in the treatment of infections caused by slow-growing bacteria, such as Mycobacterium tuberculosis [2].

Aminoglycosides are primarily eliminated by renal excretion, and their dosing must be adjusted in patients with impaired renal function to prevent toxicity. Aminoglycosides are also associated with a number of toxicities, including nephrotoxicity, ototoxicity, and neuromuscular blockade. These toxicities are dosedependent and can be minimized by careful monitoring of serum drug concentrations and renal function [3].

The use of aminoglycosides in clinical practice is governed by a number of factors, including the severity of the infection, the susceptibility of the causative organism, and the presence of comorbidities. Aminoglycosides are often used in combination with other antibiotics, particularly beta-lactams, to achieve synergistic activity against certain organisms.

Aminoglycosides have been used extensively in the treatment of a variety of infections, including pneumonia, sepsis, and endocarditis. They are also used prophylactically in certain surgical procedures to prevent post-operative infections. However, the emergence of antibiotic resistance has limited the usefulness of aminoglycosides in some settings, particularly in the treatment of nosocomial infections [4].

Conclusion

Aminoglycosides are a class of antibiotics with potent bactericidal activity and a rapid onset of action. They are particularly effective against Gram-negative bacteria, but also have activity against some Gram-positive organisms. Aminoglycosides are administered parenterally and are associated with a number of toxicities, particularly nephrotoxicity and ototoxicity. Their use in clinical practice is governed by a number of factors, including the severity of the infection, the susceptibility of the causative organism, and the presence of co-morbidities. Despite their limitations, aminoglycosides remain an important class of antibiotics in the treatment of certain infections.

References

1. Schatz A, Bugle E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Clin Orthop Relat Res. 1944;55(1):66-69.

   [Google Scholar] [PubMed] [Crossref]

2. Takahashi Y, Igarashi M. Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’. J Antibiot. 2018;71(1):4-14.

   [Google Scholar] [PubMed] [Crossref]

3. François B, Russell RJ, Murray JB, Aboul-ela F, Masquida B, Vicens Q, et al. Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res. 2005;33(17):5677-5690.

   [Google Scholar] [PubMed] [Crossref]

4. Pape T, Wintermeyer W, Rodnina MV. Conformational switch in the decoding region of 16S rRNA during aminoacyl-tRNA selection on the ribosome. Nat Struct Biol.. 2000;7(2):104-107.

   [Google Scholar] [PubMed] [Crossref]